Parth Narendran
Overview
Explore the profile of Parth Narendran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
1255
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rengarajan L, Cooper C, Malhotra K, Sharma A, Philip N, Abraham A, et al.
Diabet Med
. 2025 Feb;
:e70004.
PMID: 39957319
Aim: A current gap in Diabetes-related ketoacidosis (DKA) research is understanding the factors contributing to variations in care and outcomes between people admitted with DKA. We aimed to create a...
2.
Sharma A, Rengarajan L, Narendran P, Dhatariya K, Kempegowda P
Diabet Med
. 2025 Feb;
:e70010.
PMID: 39928758
Aims: The Joint British Diabetes Society-Inpatient (JBDS-IP) group recommends reducing fixed rate intravenous insulin infusion (FRIII) from 0.1 to 0.05 units/kg/h when blood glucose falls <14 mmol/L to reduce the...
3.
Hoffmann L, Kohls M, Arnolds S, Achenbach P, Bergholdt R, Bonifacio E, et al.
BMJ Open
. 2025 Jan;
15(1):e088522.
PMID: 39753267
Introduction: The identification of type 1 diabetes at an early presymptomatic stage has clinical benefits. These include a reduced risk of diabetic ketoacidosis (DKA) at the clinical manifestation of the...
4.
Narendran P, Newland-Jones P, Kanumilli N, Stewart R, Regan F, Randell T
Diabet Med
. 2024 Dec;
:e15508.
PMID: 39733443
No abstract available.
5.
Quinn L, Dias R, Greenfield S, Richter A, Garstang J, Shukla D, et al.
Diabet Med
. 2024 Dec;
:e15490.
PMID: 39623620
Aim: The EarLy Surveillance for Autoimmune (ELSA) study aims to explore the feasibility and acceptability of UK paediatric general population screening for type 1 diabetes. Methods: We aim to screen...
6.
Ng S, Price M, Richardson N, Nawaf M, Copland A, Streeter H, et al.
Diabetes
. 2024 Nov;
74(3):384-397.
PMID: 39571092
Article Highlights: There are currently no approved antigen-specific immunotherapies (ASIs) for people with type 1 diabetes (T1D). We aimed to develop a peptide for ASI for T1D based on the...
7.
Gupta A, Brazier B, Rengarajan L, Narendran P, Kempegowda P
Clin Med (Lond)
. 2024 Oct;
24(6):100255.
PMID: 39427769
There are significant variations in discharge post-diabetes-related ketoacidosis (DKA) hospitalisation, yet there is a paucity of research to understand or minimise the reasons. This quality improvement project (QIP) aimed to...
8.
Quinn L, Dias R, Bidder C, Bhowmik S, Bumke K, Ganapathi J, et al.
BMJ Open Diabetes Res Care
. 2024 Sep;
12(5).
PMID: 39327068
Introduction: We describe the identification and management of general population screen-detected type 1 diabetes (T1D) and share learnings for best practice. Research Design And Methods: Children diagnosed with T1D through...
9.
Rao A, Quinn L, Narendran P
Clin Diabetes Endocrinol
. 2024 Sep;
10(1):26.
PMID: 39252097
Background: Type 1 diabetes mellitus (T1D) is an autoimmune disease caused by destruction of pancreatic islet beta-cells. There is significant residual beta-cell function, measured through circulating C-peptide, present at the...
10.
Quickfall M, Cocks M, Long H, Di Rosa F, Andrews R, Narendran P, et al.
BMJ Open Sport Exerc Med
. 2024 Sep;
10(3):e002144.
PMID: 39224197
Type 1 diabetes (T1D) is a chronic autoimmune disease in which the adaptive immune system targets insulin-producing β-cells of pancreatic islets, leading to dependence on exogenous insulin therapy. Cytotoxic (CD8)...